Motixafortide: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Motixafortide. Educational only — not medical advice.

Labeled uses

APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

Source: FDA labeling via NIH DailyMed (set e704b2db…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.